Oftalmol Zh.2013;2:48-50

https://doi.org/10.31288/oftalmolzh201324850

Prevention and treatment of macular degeneration and eye posterior pole

N. V. Konovalova, N. I. Naritsyna, A. Ya. Novik, A. V. Rybalko

SI «Filatov Institute of Eye Diseases and Tissue Therapy of National Academy of Medical Sciences of the Ukraine»

The use of the drug Ocuvite Complete 1 capsule two times for four months helped to stabilize visual function in 83 % of patients and improve visual acuity in 26.3 % of  ofpatients. Ocuvite complete serves to prevent the development of degeneration macula and posterior poles and contributes to the stabilization of visual function.

Key words: macular degeneration and posterior pole, Ocuvite Complete

References
1.Кански Дж. Дж. Заболевания глазного дна / Дж.Дж. Кански // Под ред. С. Э. Аветисова. — М., 2008. — 3153 с.
2.Морозов В. И. Фармакотерапия глазных болезней / В. И. Морозов, А. А. Яковлев // М.: Медицина. — 2004. — 512 с.
3.Brown D. M. Ranibizumab versus verteporfm for neovas-cular age-related macular degeneration / D. M. Brown, P. K. Kaiser, М. Michels // N. Engl. J. Med. — 2006. — Vol. 5. — P. 1432— 1444
Crossref
4.Carneiro A. M. Arterial Thromboembolic Events in Patients with  Exudative  Age-Related  Macular Degeneration Treated with Intravitreal Bevacizumab or Ranibizumab/А. М. Carneiro // Ophthalmologica. — 2011. — Feb.18. — P.211-225
Crossref
5.Gaudreault J. Preclinical pharmacokinetics of Ranibizumab (rhuRabV2) after a single intravitrical administration/ J. Gaudreault, D. Fei, J. Rusit // Invest. Ophthalmol. — 2005. — Vol. — 46. — P. 726- 733.
Crossref
6.Regillo C. D. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1/ C. D. Regillo, D. M. Brown, P. Abraham // Am. J. Ophthalmol. — 2008. — Vol. 145. — P. 239- 248.
Crossref
7.Towler H. Age related macular degeneration // H. Towler, S. Lightman / British Medical Journal Ophthalmology. — 1996. — V.312. — P.89- 92.
Crossref